

Efficacy of a Novel Spreadsheet Program for Pharmacy-based

Antiretroviral (ARV) Monitoring in Southern Africa

Imbi Ichile, PharmD, Nicole Butts, PharmD, Jamie Holmes, PharmD, James Alexander, PharmD, Joseph Barone, PharmD, Humberto Jimenez, PharmD, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ

Background


ARV Monitoring Program


Table 1. Internal Adherence Calculation Tool

Equation #1: (# of tablets dispensed - # of tablets missed) (# of tablets dispensed) x 100 = % Adherence Equation #2: (# of tablets dispensed - # of tablets missed)/(# of tablets per day) (# of days between refills)

*Equation selection depended upon the information-gathering capacity and the desired findings at each site. *Pharmacy staff were instructed to identify courseling opportunities based on results of adherence calculation b Adherence >95% considered "good", 55-55% considered "fair", 455% considered "fair", 455% considered "fair",

Figure 2. Adherence and Patient Tracking









Table 2. Beneficiary Evaluation: Need



🔲 Strongly Agree 🔳 Agree 🔳 Neutral 🛄 Somewhat Disagree 🗐 Strongly Disagree

Evaluation

Bristol-Myers Squibb Company

- ARV monitoring program introduced at each site in September of 2009. At Senkatana Centre, it was monitored and consistently modified by resident over a period of 4 months, with the provision of training and education
- Program evaluated via a general survey about the PharmD resident's performance and PharmD observation/verbal userfeedback

Discussion/Limitations

- Operational manual best-utilized by those staff with advanced education (ie: pharmacy technician with 3-year diploma or pharmacist)
- Continuous use of ARV monitoring tool, with appropriate education, enabled staff to make more complete assessment of a patients' drug therapy with more efficient, individualized counseling
- Enhanced provider knowledge, as an outcome, was observed
- Majority of observers or users were either agreeable or strongly agreeable to its implementation (Table 2)

Limitations included.

- Staff belief that only new-start patients need to be documented
- Lack of formal evaluation from users or observers at LPH
- Cross-tabulation of spreadsheet program evaluations vs. PharmD performance evaluation
- Enhanced patient safety and strengthened ability to keep patients on 1st-line regimen, with "more rational, safe use of medications" as an outcome will need to be observed over time

Next Steps

- Continuous improvement to program based on user feedback and persistence in providing training
- · Formal evaluation from all sites
- Evaluation specific to PV Spreadsheet Program
- Division of operation manual into a more basic version and more advanced version
- Further education about detection of ADRs and how to calculate adherence

Acknowledgements / Disclosures

The authors would like to recognize the following individuals for their contribution to the development of this poster:

 Senkatana Centre Staff
Phangisile Mtshali, BMS Director External Affairs
John Damonti, BMS VP of Corporate Philanthropy

Authors of this presentation have nothing to disclose concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this presentation.

Government-led efforts have expanded ARV access to rural populations in southern Africa However, limited medication choices have

- subjected patients to frequent adverse drug reactions (ADRs), calling for an enhanced need for efficient drug monitoring
- Many treatment centers have undeveloped monitoring programs
- Limited pharmacy resources are funneled toward dispensing and related functions
- A unique pharmacy residency was created by Rutgers University and Bristol-Myers Squibb's Secure the Future to study and assist in the delivery of enhanced pharmacy services for people living with HIV/AIDS.
- The Doctor of Pharmacy (PharmD) resident created an innovative monitoring program for pharmacy staff at multiple locations
- The program facilitated longitudinal ARV monitoring using a spreadsheet-based pharmacovigilance (PV) tool to track patients on ARVs.

Objectives and expected outcomes of the PV monitoring program are described in Figure 1.

Purpose

- Monitor patient adherence to ARVs (Fig 2)
- Monitor ADRs experienced by patients on ARVs (Fig 3)

Methodology

- ARV monitoring program implemented at 2 sites: <u>Senkatana Centre in Lesotho</u>; later adapted to the <u>Ladysmith Provincial Hospital</u> (LPH) in KwaZulu Natal, South Africa
- **PV monitoring tool** developed to capture key demographic and clinical patient data (*Figures 2 and 3*)
- Internal adherence calculation tool imbedded in spreadsheet to assess patients' medication adherence (Table 1)
- Operational manuals developed and tailored to each site; manuals later combined to create single comprehensive guide, applicable throughout the region
- Program at LPH was mainly demonstrative (training); program at Senkatana Centre pharmacy consisted of full integration with close follow-up observation
- PharmD resident conducted live demonstration of **PV monitoring tool** at the Lesotho Ministry of Health as means of promoting nationwide usage

Figure 1. Objectives and Expected Outcomes of ARV Monitoring



 More rational, safe use of drugs through local, national, and international guideline changes
Improved patient care in relation to ARVs and HIVrelated medication

3. Improved communication to the public \rightarrow improve public trust in healthcare systems



n SECURE THE FUTURE